After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
The company will imminently start its third pivotal trial of PF-08634404.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The company ditches lorigerlimab in prostate cancer.
But the Day One deal is still 29% below where the shares stood at the start of this year.
